Anixa Biosciences CEO Discusses Breakthroughs in Cancer Treatment on Podcast In a recent podcast, Anixa Biosciences' CEO shared insights on innovative cancer treatments, including advances in their clinical trials and future plans.

Anixa Biosciences CEO Discusses Breakthroughs in Cancer Treatment on Podcast #United_States #Anixa_Biosciences #San_Jose #Cancer_Treatments #Podcast

EGFR-NSCLC Market Expected to Grow at a CAGR of 9.6% from 2025 to 2034 The EGFR-NSCLC market is projected to expand significantly with a 9.6% CAGR between 2025 and 2034, driven by new treatments and increased patient identification.

EGFR-NSCLC Market Expected to Grow at a CAGR of 9.6% from 2025 to 2034 #USA #Las_Vegas #Cancer_Treatments #DelveInsight #EGFR-NSCLC

Global Oncology Drug Market Expected to Surpass $335 Billion by 2033 with Growth at 7.2% CAGR A new report projects the oncology/cancer drugs market to reach $335.2 billion by 2033, driven by increased awareness and demand for targeted treatments.

Global Oncology Drug Market Expected to Surpass $335 Billion by 2033 with Growth at 7.2% CAGR #None #Cancer_Treatments #targeted_therapies #Oncology_Drugs

TIGIT Inhibitors Market Set for Significant Expansion Driven by Enhanced Immuno-Oncology Solutions The TIGIT inhibitors market is poised for substantial growth through 2034, influenced by rising cancer diagnoses and new immuno-oncology treatments.

TIGIT Inhibitors Market Set for Significant Expansion Driven by Enhanced Immuno-Oncology Solutions #United_States #Las_Vegas #Cancer_Treatments #Immuno-Oncology #TIGIT_Inhibitors

Interventional Oncology Market Growth Forecast: $4.38 Billion by 2030 at 8.55% CAGR The interventional oncology market is set to grow to $4.38 billion by 2030, driven by increasing cancer rates and advancements in technology.

Interventional Oncology Market Growth Forecast: $4.38 Billion by 2030 at 8.55% CAGR #USA #San_Francisco #Cancer_Treatments #Oncology_Market #Interventional_Oncology

Precision Oncology Approaches Transform $312 Billion Market Landscape with Innovative Treatments The global precision oncology market is rapidly changing as innovative biomarker-driven therapies are developed, addressing previously untreatable cancers and enhancing outcomes.

Precision Oncology Approaches Transform $312 Billion Market Landscape with Innovative Treatments #USA #San_Francisco #Cancer_Treatments #Precision_Oncology #GT_Biopharma

Next-Generation Targeted Therapies Transform the Precision Oncology Landscape The rise of biomarker-driven drug development is revolutionizing oncology, leading to innovative therapies that target hard-to-treat cancers and enhance patient outcomes.

Next-Generation Targeted Therapies Transform the Precision Oncology Landscape #USA #San_Francisco #Cancer_Treatments #Precision_Oncology #GT_Biopharma

Oncology Therapy Market Forecast to Reach $440 Billion by 2033 Driven by Innovations and Rising Cancer Cases The oncology therapy sector is set to expand significantly, projected to hit $440 billion by 2033, predominantly due to innovation and increasing cancer rates globally.

Oncology Therapy Market Forecast to Reach $440 Billion by 2033 Driven by Innovations and Rising Cancer Cases #India #Cancer_Treatments #Hyderabad #DataM_Intelligence #Oncology_Therapy

Emerging Oncology Stocks Thrive Amid National Cancer Institute Budget Concerns As cancer rates rise and drug costs increase, emerging oncology stocks are gaining investor attention amid NCI funding cuts.

Emerging Oncology Stocks Thrive Amid National Cancer Institute Budget Concerns #USA #Vancouver #Cancer_Treatments #Oncolytics_Biotech #Oncology_Stocks

The Future of Cancer Treatment: Will Biotech Lead the $900 Billion Market? With the oncology drug market projected to exceed $900 billion by 2034, the spotlight shifts to biotech firms innovating cancer treatments amid funding challenges.

The Future of Cancer Treatment: Will Biotech Lead the $900 Billion Market? #USA #Vancouver #Cancer_Treatments #Oncolytics_Biotech #Oncology_Drugs

The Future of HER2+ Gastric Cancer Treatment: Insights into Market Growth and Innovations Explore the promising growth of the HER2+ gastric cancer market, expected to expand by 13% until 2034, driven by innovative therapies and treatment advancements.

The Future of HER2+ Gastric Cancer Treatment: Insights into Market Growth and Innovations #None #Cancer_Treatments #HER2+_Gastric_Cancer #Oncology_Therapies

The Evolving Landscape of Anal Cancer Treatments: Incyte's Zynyz Takes Center Stage The anal cancer treatment market is evolving rapidly, led by Incyte's PD-1 inhibitor Zynyz and its competitive landscape involving Merck, Novartis, and others.

The Evolving Landscape of Anal Cancer Treatments: Incyte's Zynyz Takes Center Stage #USA #Las_Vegas #Cancer_Treatments #Incyte_Zynyz #Anal_Cancer

Biohaven Reveals Promising Results of Oncology Programs Featuring Novel Antibody Drug Conjugates Biohaven shared recent developments in its oncology efforts, showcasing the potential of innovative antibody drug conjugates targeting various tumors, including promising clinical findings.

Biohaven Reveals Promising Results of Oncology Programs Featuring Novel Antibody Drug Conjugates #USA #Cancer_Treatments #Biohaven #New_Haven #antibody_drug_conjugates

FLASCO Releases New White Paper to Enhance Access to Life-Saving Cancer Treatments The Florida Society of Clinical Oncology has published a new white paper focusing on improving access to innovative cancer therapies in Florida.

FLASCO Releases New White Paper to Enhance Access to Life-Saving Cancer Treatments #United_States #Cancer_Treatments #FLASCO #innovative_therapies #Riverview

Evolent Health's Program Reduces Low-Value Cancer Treatments by 20% Evolent Health has successfully reduced the use of low-value cancer treatments by over 20%, improving patient care and managing costs through innovative provider engagement strategies.

Evolent Health's Program Reduces Low-Value Cancer Treatments by 20% #USA #Washington #Cancer_Treatments #Evolent_Health #oncology_regimens

Rigel Pharmaceuticals Announces Participation in J.P. Morgan Healthcare Conference 2025 Rigel Pharmaceuticals, Inc. will showcase its innovative therapies for hematologic disorders and cancer at the annual J.P. Morgan Healthcare Conference.

Rigel Pharmaceuticals Announces Participation in J.P. Morgan Healthcare Conference 2025 #United_States #San_Francisco #Cancer_Treatments #Healthcare_Conference #Rigel_Pharmaceuticals

General Proximity Secures $16M to Revolutionize Treatments for 'Undruggable' Diseases With $16 million in new funding, General Proximity aims to advance its innovative medicines targeting undruggable proteins linked to various diseases.

General Proximity Secures $16M to Revolutionize Treatments for 'Undruggable' Diseases #United_States #San_Francisco #Cancer_Treatments #General_Proximity #OmniTAC

Innovative Therapies Revolutionizing Cancer Treatment: A New Era in Oncology Explore how emerging immunotherapies are reshaping cancer treatment, with groundbreaking advancements from key industry players in oncology.

Innovative Therapies Revolutionizing Cancer Treatment: A New Era in Oncology #USA #Vancouver #Immunotherapy #Cancer_Treatments #Oncolytics_Biotech

Transformative Advances in Cancer Care through Innovative Immunotherapies Recent breakthroughs in immunotherapy are reshaping cancer care, offering new hope to patients with advanced cancer through innovative treatments.

Transformative Advances in Cancer Care through Innovative Immunotherapies #USA #Vancouver #Immunotherapy #Cancer_Treatments #Oncolytics_Biotech

Expected Growth of Germ Cell Tumors Market with Novel Treatments and Enhanced Access to Care The Germ Cell Tumors market is projected to grow significantly by 2034, driven by innovative treatments and expanding patient access globally.

Expected Growth of Germ Cell Tumors Market with Novel Treatments and Enhanced Access to Care #None #Cancer_Treatments #DelveInsight #Germ_Cell_Tumors

Global Cancer Cases Surge Despite Advances in Biotech Treatments with FDA Approvals A global rise in cancer cases among younger populations persists, even as biotech advancements lead to new FDA oncology treatments, including significant breakthroughs.

Global Cancer Cases Surge Despite Advances in Biotech Treatments with FDA Approvals #USA #Vancouver #Cancer_Treatments #Oncolytics_Biotech #FDA_oncology

Adcendo ApS Completes $135 Million Series B Financing to Enhance ADC Development for Cancer Treatments Adcendo, a biotech company, raised $135 million in Series B financing to accelerate its development of antibody-drug conjugates designed for difficult cancers.

Adcendo ApS Completes $135 Million Series B Financing to Enhance ADC Development for Cancer Treatments #Denmark #Copenhagen #Adcendo #ADC #Cancer_Treatments